Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Phase 1 demonstrates LYT-100 (deupirfenidone) is dose-proportional and well-tolerated when given twice-daily over multiple ascending doses (MAD) and shows a minor food effect (FE) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008
A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Nonclinical safety profiles of DS-1515, a novel oral PI3Kd inhibitor. Source: International Congress 2018 – Basic pharmacology Year: 2018
INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019
Indacaterol, a novel β2 -agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010